Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
Standard
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. / Ludwig, Heinz; Pönisch, Wolfram; Knop, Stefan; Egle, Alexander; Hinke, Axel; Schreder, Martin; Lechner, Daniel; Hajek, Roman; Gunsilius, Eberhard; Petzer, Andreas; Weisel, Katja; Niederwieser, Dietger; Einsele, Hermann; Willenbacher, Wolfgang; Rumpold, Holger; Pour, Ludek; Jelinek, Tomas; Krenosz, Karl Jochen; Meckl, Angela; Nolte, Sandra; Melchardt, Thomas; Greil, Richard; Zojer, Niklas.
in: LEUKEMIA LYMPHOMA, Jahrgang 61, Nr. 2, 02.2020, S. 377-386.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
AU - Ludwig, Heinz
AU - Pönisch, Wolfram
AU - Knop, Stefan
AU - Egle, Alexander
AU - Hinke, Axel
AU - Schreder, Martin
AU - Lechner, Daniel
AU - Hajek, Roman
AU - Gunsilius, Eberhard
AU - Petzer, Andreas
AU - Weisel, Katja
AU - Niederwieser, Dietger
AU - Einsele, Hermann
AU - Willenbacher, Wolfgang
AU - Rumpold, Holger
AU - Pour, Ludek
AU - Jelinek, Tomas
AU - Krenosz, Karl Jochen
AU - Meckl, Angela
AU - Nolte, Sandra
AU - Melchardt, Thomas
AU - Greil, Richard
AU - Zojer, Niklas
PY - 2020/2
Y1 - 2020/2
N2 - This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy. When patient's baseline QoL was compared with data of the general population, a significant impairment in health-related QoL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, was noted. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant variation of other parameters. During maintenance treatment, scores for most dimensions including health-related QoL, physical functioning and pain, improved, while for neuropathy no improvement was observed. Time to deterioration (≥10 score points) of health-related QoL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QoL and physical functioning at baseline correlated with overall survival.
AB - This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy. When patient's baseline QoL was compared with data of the general population, a significant impairment in health-related QoL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, was noted. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant variation of other parameters. During maintenance treatment, scores for most dimensions including health-related QoL, physical functioning and pain, improved, while for neuropathy no improvement was observed. Time to deterioration (≥10 score points) of health-related QoL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QoL and physical functioning at baseline correlated with overall survival.
U2 - 10.1080/10428194.2019.1666381
DO - 10.1080/10428194.2019.1666381
M3 - SCORING: Journal article
C2 - 31556753
VL - 61
SP - 377
EP - 386
JO - LEUKEMIA LYMPHOMA
JF - LEUKEMIA LYMPHOMA
SN - 1042-8194
IS - 2
ER -